Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Elanco Animal Health (ELAN)
NYSE:ELAN
RESEARCH TOOLSreports
Holding ELAN?
Track your performance easily
ELAN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$11.40 - $18.80
Previous Close$13.44
Volume4.56M
Average Volume (3M)4.46M
Market Cap
$6.58B
Enterprise Value$10.45B
Total Cash (Recent Filing)$490.00M
Total Debt (Recent Filing)$4.36B
Price to Earnings (P/E)32.9
Beta1.92
Next Earnings
Feb 19, 2025EPS Estimate
$0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.41
Shares Outstanding494,352,808
10 Day Avg. Volume4,565,630
30 Day Avg. Volume4,455,039
Standard Deviation0.14
R-Squared0.29
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.02
Price to Sales (P/S)1.48
Price to Cash Flow (P/CF)10.20
P/FCF Ratio11.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.35
Enterprise Value/Gross Profit4.20
Enterprise Value/Ebitda14.97
Forecast
1Y Price Target
$18.29Price Target Upside36.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Elanco Animal Health News
Bulls Say, Bears Say
Bulls Say
Investor ConfidenceElanco's management committed to mid single digit organic sales growth and low single digit adjusted EBITDA growth for 2025, which was well-received by investors.
Market OpportunityZenrelia's unique offering of a QD administration, comparable efficacy to market leader, Apoquel, and importantly - its lower launch price - which remains a key barrier for pet owners.
Product InnovationThe focus for Elanco remains Innovation, with products like Zenrelia, Credelio Quattro, Bovaer, Experior, and AdTab expected to contribute significantly to growth.
Bears Say
Competitive LandscapeThe evolving competitive landscape presents challenges, with near-term contributions not without risks amidst a potentially increasingly competitive landscape in dermatology/parasiticides.
Product AdoptionConcerns exist that the presence of a warning label on Zenrelia may slow adoption due to fears of legal or reputational risk.
Product Safety And ComplexityThe boxed warning on safety was based on the outcome of a trial with unvaccinated dogs dosed at 3x the label dose, where dogs experienced drug-induced immunosuppression, resulting in fatal vaccine-induced disease.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ELAN FAQ
What was Elanco Animal Health’s price range in the past 12 months?
Elanco Animal Health lowest stock price was $11.40 and its highest was $18.80 in the past 12 months.
What is Elanco Animal Health’s market cap?
Currently, no data Available
When is Elanco Animal Health’s upcoming earnings report date?
Elanco Animal Health’s upcoming earnings report date is Feb 19, 2025 which is in 89 days.
How were Elanco Animal Health’s earnings last quarter?
Elanco Animal Health released its earnings results on Nov 07, 2024. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.122 by $0.008.
Is Elanco Animal Health overvalued?
According to Wall Street analysts Elanco Animal Health’s price is currently Undervalued.
Does Elanco Animal Health pay dividends?
Elanco Animal Health does not currently pay dividends.
What is Elanco Animal Health’s EPS estimate?
Elanco Animal Health’s EPS estimate is $0.15.
How many shares outstanding does Elanco Animal Health have?
Elanco Animal Health has 494,352,800 shares outstanding.
What happened to Elanco Animal Health’s price movement after its last earnings report?
Elanco Animal Health reported an EPS of $0.13 in its last earnings report, beating expectations of $0.122. Following the earnings report the stock price went up 12.753%.
Which hedge fund is a major shareholder of Elanco Animal Health?
Among the largest hedge funds holding Elanco Animal Health’s share is Dodge & Cox. It holds Elanco Animal Health’s shares valued at 1B.
---
Elanco Animal Health Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.29 (36.49% Upside)
$18.29 (36.49% Upside)
Blogger Sentiment
Bullish
ELAN Sentiment 60%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $51.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 11.4%
Last 30 Days ▼ 11.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
13.13%
12-Months-Change
Fundamentals
Return on Equity
3.24%
Trailing 12-Months
Asset Growth
-7.40%
Trailing 12-Months
Company Description
Elanco Animal Health
Elanco Animal Health, Inc. engages in the innovation, development, manufacture and market products for companion and food animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded on May 3, 2018 and is headquartered in Greenfield, IN.
---
ELAN Company Deck
---
ELAN Earnings Call
Q3 2024
0:00 / 0:00
---
ELAN Stock 12 Month Forecast
Average Price Target
$18.29
▲(36.49% Upside)
Technical Analysis
Best Analysts Covering ELAN
1 Year
1 Year Success Rate
10/17 ratings generated profit
1 Year Average Return
+11.78%
reiterated a buy rating 16 days ago
Copying Michael Ryskin's trades and holding each position for 1 Year would result in 58.82% of your transactions generating a profit, with an average return of +11.78% per trade.
---